Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells.

23 Sep 2010

Miltenyi Biotec releases ACSA-1 MicroBead Kit to isolate GLAST-expressing astrocytes

Miltenyi Biotec announces the worldwide first and exclusive release of the Anti-GLAST (ACSA-1) MicroBead Kit. Isolation of viable GLAST-expressing astrocytes is now possible within one hour using the first commercially available antibody against an extracellular surface epitope of GLAST.

23 Sep 2010

Scientists identify genetic variants that increase asthma susceptibility

An international study looking at DNA from over 26,000 people has identified several genetic variants that substantially increase susceptibility to asthma in the population. The findings, published in the New England Journal of Medicine, will help scientists to focus their efforts to develop better therapies for the illness.

23 Sep 2010

Generex presents study results of Oral-lyn insulin spray at EASD Annual Meeting

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes being held in Stockholm, Sweden, 20 - 24 September, 2010.

23 Sep 2010

Diagenode releases two monoclonal antibodies to enrich 5-hmC epigenetics research

Diagenode announced today that it has released two additional 5-hmC antibodies to complement its original 5-hmC (rat) monoclonal antibody. The two new 5-hmC monoclonal antibody (mouse) and polyclonal antibody (rabbit) antibodies give researchers additional choices for enriching and analyzing 5-hmC in their methylation studies.

23 Sep 2010

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics Pharmaceuticals, Inc. today announced the completion of the treatment phase of a 1,034-patient, one-year, open-label, international, phase 3 safety study of methylnaltrexone bromide subcutaneous injection in chronic, non-malignant pain patients with opioid-induced constipation (OIC).

22 Sep 2010

Researchers receive $634,000 grant to study environmental factors, MS progression

A $634,000 grant from the Department of Defense is allowing researchers at the University at Buffalo to investigate a trio of environmental factors and their influence on the progression of multiple sclerosis.

22 Sep 2010

UC researcher receives NIDA’s Avant-Garde Award for cocaine addiction research

A University of Cincinnati (UC) researcher will receive $2.5 million over five years from the National Institute on Drug Abuse (NIDA) to support his work on a potential immunotherapy for cocaine addiction.

22 Sep 2010

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

A potential immunotherapy, a new gene therapy, an enzyme inhibitor, and a compound originally isolated from a Chinese herb are among the latest approaches scientists are proposing to treat addiction.

22 Sep 2010

Study demonstrates why targeted therapies do not work in majority of people

In order for targeted therapies against cancer to be effective, scientists need to understand upfront what related proteins in a signaling "network" makes a cancer cell resistant to a drug and selectively target them as well, say researchers at Georgetown Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center.

22 Sep 2010

FDA grants Phadia 510(k) clearance for CLIA Moderate Complexity, EliA autoimmune antibody assays

Today Phadia announced that it has received FDA 510(k) clearance for two new, CLIA Moderate Complexity, EliA autoimmune antibody assays. The new assays will provide physicians with additional tools needed to aid in the diagnosis of Celiac disease. The newly available assays, EliA GliadinDP IgA and EliA GliadinDP IgG (deamidated peptides), have proven to be essential, sensitive and specific markers to aid in the diagnosis of celiac disease.

22 Sep 2010

Five Prime Therapeutics receives patent for lead oncology product

Five Prime Therapeutics, Inc. today announced it has been issued two patents, U.S. Patent No. 7,678,890 and European Patent No.1910542B1, with claims covering various engineered Fibroblast Growth Factor Receptor ("FGFR") fusion proteins, including composition of matter claims for its lead oncology product, FP-1039.

21 Sep 2010

Health Canada issues license for IgX PLEX Celiac test kit

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, announced today that Health Canada has issued a medical device license for its automated IgX PLEX Celiac(TM) microarray test kit that runs on the Company's automated SQiDworks(TM) platform. The license allows the Company to market and sell the IgX PLEX Celiac product in Canada.

21 Sep 2010

ImmunoGen commences clinical testing with SAR566658 anticancer compound

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the start of clinical testing with SAR566658. Eight compounds are now in the clinic through ImmunoGen's product programs and those of its partners, consistent with Company expectations of as many as 12 such compounds being in the clinic by late 2011 and marked, sustained pipeline growth thereafter.

21 Sep 2010

Researchers to develop vaccine for plague

Given the many pressing concerns of the day, fear of plague probably isn't what causes most Americans to lose sleep. But for those whose responsibility it is to combat bioterrorism, plague is among the highest priorities. Those charged with that mission include scientists like medical researcher Steve Smiley, whose lab at the Trudeau Institute is working to develop a vaccine that will protect the public against weaponized forms of plague.

21 Sep 2010

Childhood obesity linked to common cold virus

A new study has shown that obese children are more prone to carrying a common cold virus than slimmer children. The virus in question is adenovirus 36 and if the link is true then someday new obesity treatments might be tailored to attack the virus to treat or prevent childhood obesity. Childhood obesity affects 17% of American children and adolescents. The report appeared in the journal Pediatrics.

21 Sep 2010

Dengue fever vaccine in the pipeline

Australians researchers are moving towards producing the first ever vaccine for dengue fever, the potentially life-threatening infection spread by mosquitoes in the tropics. At present late stage clinical trials are underway for a vaccine that would protect against all four known strains of the disease. Participants are now being recruited in Perth, Adelaide and Brisbane.

20 Sep 2010

MJFF selects Epitomics to distribute LRRK2 monoclonal antibodies

Epitomics, Inc. today announced that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has chosen the company to distribute a panel of LRRK2 monoclonal antibodies that were developed under an agreement between the two parties. Under a special arrangement the antibodies are being provided at low cost to the entire PD research community to help advance LRRK2 therapeutic development efforts. The antibodies will be available to Parkinson's researchers in academic/nonprofit and industry labs on a worldwide basis.

20 Sep 2010

Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB

Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.

20 Sep 2010

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010

Antibody News and Research

Further Reading

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Miltenyi Biotec releases ACSA-1 MicroBead Kit to isolate GLAST-expressing astrocytes

Scientists identify genetic variants that increase asthma susceptibility

Generex presents study results of Oral-lyn insulin spray at EASD Annual Meeting

Diagenode releases two monoclonal antibodies to enrich 5-hmC epigenetics research

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Researchers receive $634,000 grant to study environmental factors, MS progression

UC researcher receives NIDA’s Avant-Garde Award for cocaine addiction research

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

Study demonstrates why targeted therapies do not work in majority of people

FDA grants Phadia 510(k) clearance for CLIA Moderate Complexity, EliA autoimmune antibody assays

Five Prime Therapeutics receives patent for lead oncology product

Health Canada issues license for IgX PLEX Celiac test kit

ImmunoGen commences clinical testing with SAR566658 anticancer compound

Researchers to develop vaccine for plague

Childhood obesity linked to common cold virus

Dengue fever vaccine in the pipeline

MJFF selects Epitomics to distribute LRRK2 monoclonal antibodies

Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB

Micromet initiates MT103 phase 2 trial in adult ALL patients

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News